Friederike S.
- Country
- France
- Department
- Medical Oncology
Research Overview
- Phase 1/2 Evaluation of EPI-7386 and Enzalutamide Combination Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
- Phase III Randomized Study of Cabazitaxel and Pelvic Radiotherapy in High-Risk Localized Prostate Cancer with Androgen Deprivation Therapy
- Phase 2 Study of Talazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced Urothelial Carcinoma
Data & Insights
Has run more than one trial at 17 of 68 partner sites.
Specializations
Prostate Cancer Management
This investigator specializes in treating various stages of prostate cancer, with particular focus on metastatic disease and novel therapeutic approaches.
- Hormone-Sensitive Prostate Cancer Treatment
- Castration-Resistant Disease Management
- High-Risk Localized Prostate Cancer
Their research encompasses targeted therapies and combination treatments for both early-stage and advanced disease states.
Advanced Therapeutic Approaches
The investigator works with innovative treatment combinations including hormone therapy, immunotherapy, and targeted agents.
- Novel Hormonal Therapy Applications
- Radiopharmaceutical Treatments
- Combination Therapy Strategies
Their work integrates multiple therapeutic modalities to address complex disease presentations.
Urological Oncology
The investigator's expertise extends to treating urological cancers, including advanced urothelial carcinoma and its variants.
- Maintenance Therapy Development
- Advanced Disease Management
- Treatment Response Assessment
Their research encompasses both localized and metastatic urological malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.